Sexual dysfunction is incredibly prevalent. According to some estimates, up to 43% of women and 31% of men will experience some form of sexual difficulty during their lifetimes.
Meanwhile, having a suboptimal sex life is a quality-of-life issue for those who are afflicted. Which means these numbers are hugely problematic.
And yet…solutions have historically been fairly limited—particularly for women.
This makes PT-141 (also known as bremelanotide) a much-needed tool in the sexual wellness toolbox.
What Is PT-141?
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist—a compound that activates a family of receptors within the central nervous system involved in regulating sexual arousal.
Unlike other medications that work peripherally (by increasing blood flow to the genitals), PT-141 acts centrally within the brain. Specifically, it binds to melanocortin receptors in the hypothalamus, thus triggering the neurochemical pathways involved in sexual desire at their source.
This central mechanism is significant because many cases of sexual dysfunction—especially low desire—are not primarily vascular problems. Rather, they have to do with how the brain processes arousal signals. PT-141 is different from other treatments in that it addresses this root issue.
FDA Approval and Regulatory History
The FDA approved PT-141 in June of 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Its path to approval was the result of two large clinical trials that enrolled over 1,200 premenopausal women who suffered from HSDD. Participants who received PT-141 reported statistically significant improvements in sexual desire, as well as less distress related to low libido.
While the FDA approval was specific to premenopausal women with HSDD, clinical research and off-label use have extended to men and postmenopausal women, with accumulating evidence of benefit across these groups.
The Brain–Body Connection
The melanocortin system is centrally involved in human sexuality. When PT-141 binds to melanocortin receptors in the hypothalamus, it activates dopaminergic pathways downstream (within the same reward circuits involved in motivation, pleasure, and anticipatory desire).
The result is an increase in sexual motivation and responsiveness. For patients whose primary complaint is absent or suppressed desire, this effect is clinically meaningful.
Use in Women
Hypoactive Sexual Desire Disorder (HSDD)
HSDD is characterized by persistently low or absent sexual desire that causes distress or interpersonal difficulty, and that is not explained by another medical condition, medication, or relationship problem. It is the most common form of female sexual dysfunction.
The women who participated in the clinical trials described above reported:
- Significant increases in satisfying sexual events per month while taking PT-141.
- Improved scores on validated desire scales (Female Sexual Function Index).
- Reduced sexual distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).
Crucially, these improvements were significant to the women themselves. When asked whether the medication made a difference for them, a significantly greater proportion of PT-141 users responded affirmatively compared to placebo.
Postmenopausal Women
Though the FDA label covers premenopausal women only, clinical data and real-world use have shown PT-141 to also be effective in postmenopausal women.
Arousal and Orgasm Difficulties
Beyond HSDD, clinicians have used PT-141 off-label for women struggling with female sexual arousal disorder (FSAD) and difficulty achieving orgasm. The medication’s activation of central dopaminergic pathways is thought to enhance responsiveness and reduce the threshold for orgasm.
Use in Men
Erectile Dysfunction
PT-141’s earliest clinical investigations were in men with erectile dysfunction (ED). Clinical trials demonstrated that men who received intranasal or subcutaneous PT-141 experienced significant improvements in erectile function. This included improvements in patients who had not responded adequately to PDE-5 inhibitors (like Cialis and Viagra).
This last point is particularly important. PDE-5 inhibitor non-responders—estimated at 30–35% of men with ED—have historically been a population of men with limited treatment options. PT-141 provides a central mechanism that bypasses the nitric oxide pathway that PDE-5 inhibitors target, offering an alternative route to improved erectile function for these men.
Male Hypoactive Sexual Desire Disorder
Men can also experience HSDD. For these patients, PT-141’s action on central arousal circuits can restore desire in ways that other solutions cannot.
Psychogenic Erectile Dysfunction
Men with psychogenic ED—where anxiety, performance pressure, or psychological factors drive the dysfunction rather than vascular or neurological pathology—may be particularly well-suited to PT-141.
By activating desire and arousal pathways centrally, the medication can help to interrupt the anxiety cycle that perpetuates psychogenic erectile dysfunction.
Administration and Dosing
PT-141 is usually administered as a subcutaneous self-injection into the abdomen or thigh, about an hour before sexual activity.
Key practical points:
- Onset—Effects typically begin within 60 minutes of injection.
- Duration—Effects last anywhere from 12–24 hours.
- No stimulation required—PT-141 does not require concurrent sexual stimulation to begin working.
Self-administered injections as a method of delivery means the medication bypasses first-pass metabolism, resulting in more predictable bioavailability.
Side Effects and Safety Considerations
PT-141 is generally well-tolerated, but it carries a well-characterized side effect profile that can be challenging for some patients. Common side effects include:
- Nausea—Nausea is usually mild and transient (among those who experience it) and usually resolves within 2 hours of onset. Taking an anti-nausea medication (such as ondansetron) 30–60 minutes before the injection reduces this side effect.
- Flushing—Some people experience transient warmth and redness, particularly of the face and neck.
- Headache—This was an issue for approximately 11% of clinical trial participants.
- Blood pressure changes—PT-141 can cause a transient decrease in blood pressure followed by a transient increase. For this reason, it’s contraindicated in patients with cardiovascular disease or uncontrolled hypertension.
The Broader Clinical Picture
Sexual dysfunction rarely exists in isolation. Commonly, it co-occurs with relationship distress, hormone imbalance, chronic illness, and medication side effects. Wherever possible, these issues should be addressed in conjunction with PT-141 use.
With that said, PT-141 provides an exciting adjunct therapy where options for those struggling with sexual dysfunction have historically been sparse.
Sexual health is an important aspect of your overall wellbeing, and treating sexual dysfunction deserves just as much rigor as any other aspect of health. Would you like to know more? Renew Youth has been helping men and women to reclaim their sex lives since 1999. To learn more, call us at (800) 859-7511 or use our easy contact form to schedule your complimentary 30-minute consultation.